ZEFIT uses zebrafish as a preclinical contract research high-throughput in vivo model for early-stage drug candidates, providing safety, efficacy, and medical relevance insights. This platform accelerates the path to commercialization by providing precise, rapid, and scalable compound evaluation. ZEFIT is developing a next-generation platform for CNS drug development, bridging the gap between early discovery and preclinical development. The high-throughput in-vivo-driven system enables rapid identification and optimization of CNS-targeting compounds, compressing the development cycle to under 3 years.

Challenges in CNS Drug Discovery:

The development of drugs for central nervous system disorders faces challenges such as poor translation from in vitro to in vivo models, leading to unreliable outcomes in later stages.

The optimization of blood-brain barrier (BBB) permeability has been found to be both expensive and inefficient.

The absence of quantitative biomarkers for evaluating the activity and progression of CNS drugs is a significant issue.

The decision-making process on candidate compounds is delayed due to insufficient in vivo data.

ZEFIT Innovative Solutions:

Zebrafish-based discovery is a cost-effective and scalable vertebrate model that provides real-time, whole-organism insights into the effects of CNS drugs.

Quantitative EEG-based biomarkers are objective indicators from biosignals that help measure brain activity and how the body responds to drugs.

In-Vivo Big Data Integration is a tool that utilizes a growing dataset of pharmacological effects to predict compound behavior early in development.



CNS-Focused Drug Discovery Platform:



ZEFIT modular, efficient CNS drug development platform utilizes high-throughput in vivo screening to quickly identify compounds with therapeutic potential for CNS disorders.

The therapeutic index optimization platform optimizes dosage ranges and treatment windows by balancing safety and efficacy.

The stability optimization platform enhances compound durability and bioavailability by assessing chemical and biological stability early.

The BBB delivery optimization platform develops and validates drug delivery methods that improve BBB permeability, utilizing in vivo metrics and real-time data to expedite results.


If you are looking for a pharmaceutical innovation, you can find them at ZEFIT.


Click here if you are interested in ZEFIT services.

View more: Advancing CNS Drug Discovery with Smart In-Vivo Science